H.C. Wainwright initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The company is focused on the neuropsychiatry space with a “novel, potentially groundbreaking variation on a well-known existing agent,” the analyst tells investors in a research note. The firm says LB’s lead candidate, LB-102, is an investigational, oral benzamide antipsychotic being developed for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric disorders, including major depressive disorder.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know
- Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy
- LB Pharmaceuticals initiated with a Buy at Craig-Hallum
- LB Pharmaceuticals files to sell 4.78M shares of common stock for holders
- LB Pharmaceuticals price target raised to $40 from $35 at Stifel